Načítá se...
Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition
PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRAS(G12C) mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathwa...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7124991/ https://ncbi.nlm.nih.gov/pubmed/31776128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3523 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|